Acute Stroke Treatment with Atorvastatin and Irbesarta

Phase 4

• Conditions: Acute Ischaemic Stroke; Stroke - Ischaemic

• Registration Number: ACTRN12605000170628
• Lead Sponsor: niversity of Western Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

All patients admitted within 72 hours of onset of symptoms will be eligible for trial entry, unless exclusion criteria are met.If a person is unable to provide informed consent the next of kin will be sought to provide consent. Patients regaining capacity will be free to continue in or withdraw from the trial.

Exclusion Criteria

Hypotension: Blood pressure less than 100mmHg systolic or 70mmHg diastolic. Hypertension (>220 mmHg) or clinical imperative to lower blood pressure. Hyperkalaemia: >5.5 mmol/L. Finger prick or laboratory blood sugar level > 13 mmol/L at baseline. Acute comorbid condition (such as myocardial ischaemia or sepsis). Active liver disease or unexplained elevation in transaminases. Already treated with ATRA, statin or more than one of an ACE inhibitor, non steroidal anti-inflammatory, potassium sparing diuretic, potassium salt or cyclosporin. Premenopausal female. Renal impairment (defined as creatinine >120 umol/L). History of sensitivity to statins, ATRA or contrast. Haemorrhage seen on initial CT.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Infarct Size[At day 30];Perfusion abnormality[At day 3]

Secondary Outcome Measures

Name	Time	Method
Markers of inflammation and vascular function (CRP, vWF, fibrinogen, E selectin, plasma isoprostanes).[At day 3 and day 30];Brain injury (S100B) and clinical outcome (MRS, MBS, NIHSS, MMSE).[At day 3 and day 30]